CORALreef Lipids Trial: What Pharmacists Should Know About Enlicitide
Ann Marie Navar, MD, PhD, explains how enlicitide’s sustained LDL-C lowering, favorable tolerability, and structured dosing may improve adherence and expand oral add-on options for patients not at goal on statins.
In an interview with Pharmacy Times, Ann Marie Navar, MD, PhD, an associate professor of internal medicine and member of the Division of Cardiology at UT Southwestern Medical Center and study investigator in the phase 3 CORALreef Lipids trial (NCT05952856), discussed longer-term efficacy, safety, and adherence findings for enlicitide (Merck & Co), an investigational oral proprotein convertase subtilisin/kexin type (PCSK9) inhibitor, and their relevance for clinical practice. Navar emphasized that the